Potential targets for intervention in radiation-induced heart disease

Current Drug Targets

Volumn 11, Issue 11, 2010, Pages 1405-1412

  Boerma, M ^a   Hauer Jensen, M ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Animal models; Endothelin system; Heart; Mast cells; Radiation; Renin angiotensin system; Sensory nerves; Transforming growth factor beta

Indexed keywords

ALKALINE PHOSPHATASE; ANGIOTENSIN II; ANTHRACYCLINE DERIVATIVE; CAPTOPRIL; CHYMASE; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIN 1; MATRIX METALLOPROTEINASE; PROTEINASE ACTIVATED RECEPTOR 2; SOMATOMEDIN C; STEM CELL FACTOR; SUBSTANCE P; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VON WILLEBRAND FACTOR;

AGE; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CELL SURVIVAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM INJURY; GENE DELETION; HEART DISEASE; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE FIBROSIS; HEART OUTPUT; HUMAN; INTERSTITIAL CELL OF CAJAL; MAST CELL; MAST CELL DEGRANULATION; MITRAL VALVE DISEASE; NERVE GROWTH; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE; RADIATION FIELD; RADIATION INDUCED HEART DISEASE; RADIATION INJURY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SENSORY NERVE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT PLANNING; UPREGULATION; ANIMAL; HEART; PATHOLOGY; RADIATION EXPOSURE; REVIEW;

ANIMALS; HEART; HEART DISEASES; HUMANS; RADIATION INJURIES;

EID: 79955013110     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450111009011405     Document Type: Article

References (156)

1. Verdecchia A, Guzzinati S, Francisci S, et al. Survival trends in European cancer patients diagnosed from 1988 to 1999. Eur J Cancer 2009; 45: 1042-66.
2. Gatta G, Zigon G, Capocaccia R, et al. Survival of European children and young adults with cancer diagnosed 1995-2002. Eur J Cancer 2009; 45: 992-1005.
3. Adams MJ, Hardenbergh PH, Constine LS, et al. Radiationassociated cardiovascular disease. Crit Rev Oncol Hematol 2003; 45: 55-75.
4. Heidenreich PA, Hancock SL, Vagelos RH, et al. Diastolic dysfunction after mediastinal irradiation. Am Heart J 2005; 150: 977-82.
5. Senkus-Konefka E, Jassem J. Cardiovascular effects of breast cancer radiotherapy. Cancer Treat Rev 2007; 33: 578-93.
6. Taylor CW, McGale P, Darby SC. Cardiac risks of breast-cancer radiotherapy: a contemporary view. Clin Oncol (R Coll Radiol) 2006; 18: 236-46.
7. Aleman BM, van den Belt-Dusebout AW, Klokman, WJ, et al. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 2003; 21: 3431-9.
8. Hooning MJ, Aleman BM, van Rosmalen AJ, et al. Cause-specific mortality in long-term survivors of breast cancer: A 25-year followup study. Int J Radiat Oncol Biol Phys 2006; 64: 1081-91.
9. Gyenes G, Rutqvist LE, Liedberg A, et al. Long-term cardiac morbidity and mortality in a randomized trial of pre-and postoperative radiation therapy versus surgery alone in primary breast cancer. Radiother Oncol 1998; 48: 185-90.
10. Cuzick J, Stewart H, Rutqvist L, et al. Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol 1994; 12: 447-53.
11. Early Breast Cancer Trialists Collaborative Group. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 2000; 355: 1757-70.
12. Borger JH, Hooning MJ, Boersma LJ, et al. Cardiotoxic effects of tangential breast irradiation in early breast cancer patients: the role of irradiated heart volume. Int J Radiat Oncol Biol Phys 2007; 69: 1131-8.
13. Darby SC, McGale P, Taylor CW, et al. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol 2005; 6: 557-65.
14. Chera BS, Rodriguez C, Morris CG, et al. Dosimetric comparison of three different involved nodal irradiation techniques for stage II hodgkin's lymphoma patients: conventional radiotherapy, intensitymodulated radiotherapy, and three-dimensional proton radiotherapy. Int J Radiat Oncol Biol Phys 2009; 75: 1173-80.
15. Tillman GF, Pawlicki T, Koong AC, et al. Preoperative versus postoperative radiotherapy for locally advanced gastroesophageal junction and proximal gastric cancers: a comparison of normal tissue radiation doses. Dis Esophagus 2008; 21: 437-44.
16. Weber DC, Peguret N, Dipasquale G, et al. Involved-Node and Involved-Field Volumetric Modulated Arc vs. Fixed Beam Intensity-Modulated Radiotherapy for Female Patients with Early-Stage Supra-Diaphragmatic Hodgkin Lymphoma: A Comparative Planning Study. Int J Radiat Oncol Biol Phys 2009; 75: 1578-86.
17. Hong TS, Crowley EM, Killoran J, et al. Considerations in treatment planning for esophageal cancer. Semin Radiat Oncol 2007; 17: 53-61.
18. Wu WC, Chan CL, Wong YW, et al. A study on the influence of breathing phases in intensity-modulated radiotherapy of lung tumours using four-dimensional CT. Br J Radiol 2010; 83: 252-6.
19. Zhang X, Li Y, Pan X, et al. Intensity-Modulated Proton Therapy Reduces the Dose to Normal Tissue Compared with Intensity-Modulated Radiation Therapy or Passive Scattering Proton Therapy and Enables Individualized Radical Radiotherapy for Extensive Stage IIIB Non-Small-Cell Lung Cancer: A Virtual Clinical Study. Int J Radiat Oncol Biol Phys 2010; 77: 357-66.
20. McGale P, Darby SC. Low doses of ionizing radiation and circulatory diseases: a systematic review of the published epidemiological evidence. Radiat Res 2005; 163: 247-57.
21. Taylor CW, Povall JM, McGale P, et al. Cardiac dose from tangential breast cancer radiotherapy in the year 2006. Int J Radiat Oncol Biol Phys 2008; 72: 501-7.
22. Demirci S, Nam J, Hubbs JL, et al. Radiation-induced cardiac toxicity after therapy for breast cancer: interaction between treatment era and follow-up duration. Int J Radiat Oncol Biol Phys 2009; 73: 980-7.
23. Hardenbergh PH, Munley MT, Bentel GC, et al. Cardiac perfusion changes in patients treated for breast cancer with radiation therapy and doxorubicin: preliminary results. Int J Radiat Oncol Biol Phys 2001; 49: 1023-8.
24. Prosnitz RG, Hubbs JL, Evans ES, et al. Prospective assessment of radiotherapy-associated cardiac toxicity in breast cancer patients: analysis of data 3 to 6 years after treatment. Cancer 2007; 110: 1840-50.
25. Seddon B, Cook A, Gothard L, et al. Detection of defects in myocardial perfusion imaging in patients with early breast cancer treated with radiotherapy. Radiother Oncol 2002; 64: 53-63.
26. McChesney SL, Gillette EL, Powers BE. Radiation-induced cardiomyopathy in the dog. Radiat Res 1988; 113: 120-32.
27. Schultz-Hector S, Balz K. Radiation-induced loss of endothelial alkaline phosphatase activity and development of myocardial degeneration. An ultrastructural study. Lab Investig 1994; 71: 252-60.
28. Yang VV, Stearner SP, Tyler SA. Radiation-induced changes in the fine structure of the heart: comparison of fission neutrons and 60Co gamma rays in the mouse. Radiat Res 1976; 67: 344-60.
29. Eltringham JR, Fajardo LF, Stewart JR. Adriamycin cardiomyopathy: enhanced cardiac damage in rabbits with combined drug and cardiac irradiation. Radiology 1975; 115: 471-2.
30. Labudova O, Hardmeier R, Rink H, et al. The transcription of the XRCC1 gene in the heart of radiation-resistant and radiationsensitive mice after ionizing irradiation. Pediatr Res 1997; 41: 435-9.
31. Schultz-Hector S, Trott KR. Radiation-induced cardiovascular diseases: Is the epidemiologic evidence compatible with the radiobiologic data? Int J Radiat Oncol Biol Phys 2007; 67: 10-8.
32. Hoving S, Heeneman S, Gijbels MJ, et al. Single-dose and fractionated irradiation promote initiation and progression of atherosclerosis and induce an inflammatory plaque phenotype in ApoE(-/-) mice. Int J Radiat Oncol Biol Phys 2008; 71: 848-57.
33. Stewart FA, Heeneman S, Te PJ, et al. Ionizing radiation accelerates the development of atherosclerotic lesions in ApoE-/-mice and predisposes to an inflammatory plaque phenotype prone to hemorrhage. Am J Pathol 2006; 168: 649-58.
34. Lauk S, Trott KR. Radiation induced heart disease in hypertensive rats. Int J Radiat Oncol Biol Phys 1988; 14: 109-14.
35. Gold H. Atherosclerosis in the rat. Effect of x-ray and a high fat diet. Proc Soc Exper Biol Med 1962; 111: 593-5.
36. Kitahara T, Liu K, Solanki K, et al. Functional and morphological damage after local heart irradiation and/or adriamycin in Wistar rats. Radiat Oncol Investig1993; 1: 198-205.
37. Kruse JJ, Zurcher C, Strootman EG, et al. Structural changes in the auricles of the rat heart after local ionizing irradiation. Radiother Oncol 2001; 58: 303-11.
38. Lauk S, Kiszel Z, Buschmann J, et al. Radiation-induced heart disease in rats. Int J Radiat Oncol Biol Phys 1985; 11: 801-8.
39. Hu S, Chen Y, Li L, et al. Effects of adenovirus-mediated delivery of the human hepatocyte growth factor gene in experimental radiation-induced heart disease. Int J Radiat Oncol Biol Phys 2009; 75: 1537-44.
40. Franken NA, Camps JA, Van Ravels FJ, et al. Comparison of in vivo cardiac function with ex vivo cardiac performance of the rat heart after thoracic irradiation. Br J Radiol 1997; 70: 1004-9.
41. Wondergem J, van der Laarse A, Van Ravels FJ, et al. In vitro assessment of cardiac performance after irradiation using an isolated working rat heart preparation. Int J Radiat Biol 1991; 59: 1053-68.
42. Boerma M, Wang J, Wondergem J, et al. Influence of mast cells on structural and functional manifestations of radiation-induced heart disease. Cancer Res 2005; 65: 3100-7.
43. Veinot JP, Edwards WD. Pathology of radiation-induced heart disease: a surgical and autopsy study of 27 cases. Hum Pathol 1996; 27: 766-73.
44. Brosius FC, Waller BF, Roberts WC. Radiation heart disease. Analysis of 16 young (aged 15 to 33 years) necropsy patients who received over 3,500 rads to the heart. Am J Med 1981; 70: 519-30.
45. Adams MJ, Lipsitz SR, Colan SD, et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol 2004; 22: 3139-48.
46. Hamza A, Tunick PA, Kronzon I. Echocardiographic manifestations of complications of radiation therapy. Echocardiography 2009; 26: 724-8.
47. Schultz-Hector S. Radiation-induced heart disease: review of experimental data on dose response and pathogenesis. Int J Radiat Biol 1992; 61: 149-60.
48. Wang J, Boerma M, Fu Q, et al. Significance of endothelial dysfunction in the pathogenesis of early and delayed radiation enteropathy. World J Gastroenterol 2007; 13: 3047-55.
49. Hopewell JW, Calvo W, Jaenke R, et al. Microvasculature and radiation damage. Recent Results Cancer Res 1993; 130: 1-16.
50. Fajardo LF, Stewart JR. Capillary injury preceding radiationinduced myocardial fibrosis. Radiology 1971; 101: 429-33.
51. Lauk S, Trott KR. Endothelial cell proliferation in the rat heart following local heart irradiation. Int J Radiat Biol 1990; 57: 1017-30.
52. Boerma M, Kruse JJ, van L, et al. Increased deposition of von Willebrand factor in the rat heart after local ionizing irradiation. Strahlenther Onkol 2004; 180: 109-16.
53. Baker JE, Fish BL, Su J, et al. 10 Gy total body irradiation increases risk of coronary sclerosis, degeneration of heart structure and function in a rat model. Int J Radiat Biol 2009; 85: 1089-1100.
54. Bujak M, Frangogiannis NG. The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res 2007; 74: 184-95.
55. Lim H, Zhu YZ. Role of transforming growth factor-beta in the progression of heart failure. Cell Mol Life Sci 2006; 63: 2584-96.
56. Rodemann HP, Binder A, Burger A, et al. The underlying cellular mechanism of fibrosis. Kidney Int Suppl 1996; 54: S32-6.
57. Richter KK, Langberg CW, Sung CC, et al. Association of transforming growth factor beta (TGF-beta) immunoreactivity with specific histopathologic lesions in subacute and chronic experimental radiation enteropathy. Radiother Oncol 1996; 39: 243-51.
58. Barcellos-Hoff MH. How do tissues respond to damage at the cellular level? The role of cytokines in irradiated tissues. Radiat Res 1998; 150: S109-20.
59. Scharpfenecker M, Floot B, Russell NS, et al. Endoglin haploinsufficiency reduces radiation-induced fibrosis and telangiectasia formation in mouse kidneys. Radiother Oncol 2009; 92: 484-91.
60. Kruse JJ, Floot BG, te Poele JA, et al. Radiation-induced activation of TGF-beta signaling pathways in relation to vascular damage in mouse kidneys. Radiat Res 2009; 171: 188-97.
61. Boerma M, Roberto KA, Hauer-Jensen M. Prevention and treatment of functional and structural radiation injury in the rat heart by pentoxifylline and alpha-tocopherol. Int J Radiat Oncol Biol Phys 2008; 72: 170-7.
62. Kruse JJ, Bart CI, Visser A, et al. Changes in transforming growth factor-beta (TGF-beta1), procollagen types I and III mRNA in the rat heart after irradiation. Int J Radiat Biol 1999; 75: 1429-36.
63. Liu H, Xiong M, Xia YF, et al. Studies on pentoxifylline and tocopherol combination for radiation-induced heart disease in rats. Int J Radiat Oncol Biol Phys 2009; 73: 1552-9.
64. Fyhrquist F, Saijonmaa O. Renin-angiotensin system revisited. J Intern Med 2008; 264: 224-36.
65. Ferrario CM. Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research. J Renin Ang Syst 2006; 7: 3-14.
66. Balcells E, Meng QC, Johnson WHJ, et al. Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol 1997; 273: H1769-74.
67. Sciarretta S, Paneni F, Palano F, et al. Role of the reninangiotensin-aldosterone system and inflammatory processes in the development and progression of diastolic dysfunction. Clin Sci (Lond) 2009; 116: 467-77.
68. Miyazaki M, Takai S. Tissue angiotensin II generating system by angiotensin-converting enzyme and chymase. J Pharmacol Sci 2006; 100: 391-7.
69. Lundequist A, Tchougounova E, Abrink M, et al. Cooperation between mast cell carboxypeptidase A and the chymase mouse mast cell protease 4 in the formation and degradation of angiotensin II. J Biol Chem 2004; 279: 32339-44.
70. Bader M. Role of the local renin-angiotensin system in cardiac damage: a minireview focussing on transgenic animal models. J Mol Cell Cardiol 2002; 34: 1455-62.
71. Xiao HD, Fuchs S, Bernstein EA, et al. Mice expressing ACE only in the heart show that increased cardiac angiotensin II is not associated with cardiac hypertrophy. Am J Physiol Heart Circ Physiol 2008; 294: H659-67.
72. Robbins ME, Diz DI. Pathogenic role of the renin-angiotensin system in modulating radiation-induced late effects. Int J Radiat Oncol Biol Phys 2006; 64: 6-12.
73. Moulder JE, Fish BL, Cohen EP. Treatment of radiation nephropathy with ACE inhibitors and AII type-1 and type-2 receptor antagonists. Curr Pharm Des 2007; 13: 1317-25.
74. Robbins ME, Payne V, Tommasi E, et al. The AT1 receptor antagonist, L-158,809, prevents or ameliorates fractionated wholebrain irradiation-induced cognitive impairment. Int J Radiat Oncol Biol Phys 2009; 73: 499-505.
75. Molteni A, Moulder JE, Cohen EF, et al. Control of radiationinduced pneumopathy and lung fibrosis by angiotensin-converting enzyme inhibitors and an angiotensin II type 1 receptor blocker. International Journal of Radiation Biology 2000; 76: 523-32.
76. Moulder JE, Fish BL, Cohen EP. Angiotensin II receptor antagonists in the treatment and prevention of radiation nephropathy. Int J Radiat Biol 1998; 73: 415-421.
77. Wu R, Zeng Y. Does angiotensin II-aldosterone have a role in radiation-induced heart disease? Med Hypotheses 2008; 72: 263-6.
78. Molteni A, Wolfe LF, Ward WF, et al. Effect of an angiotensin II receptor blocker and two angiotensin converting enzyme inhibitors on transforming growth factor-beta (TGF-beta) and alphaactomyosin (alpha SMA), important mediators of radiation-induced pneumopathy and lung fibrosis. Curr Pharm Des 2007; 13: 1307-16.
79. Ward WF, Molteni A, Ts'ao C, et al. The effect of Captopril on benign and malignant reactions in irradiated rat skin. Br J Radiol 1990; 63: 349-54.
80. Yarom R, Harper IS, Wynchank S, et al. Effect of captopril on changes in rats' hearts induced by long-term irradiation. Radiat Res 1993; 133: 187-97.
81. Galli SJ, Kalesnikoff J, Grimbaldeston MA, et al. Mast cells as "tunable" effector and immunoregulatory cells: recent advances. Annu Rev Immunol 2005; 23: 749-86.
82. Koskinen PK, Kovanen PT, Lindstedt KA, et al. Mast cells in acute and chronic rejection of rat cardiac allografts--a major source of basic fibroblast growth factor. Transplantation 2001; 71: 1741-7.
83. Li QY, Raza-Ahmad A, MacAulay MA, et al. The relationship of mast cells and their secreted products to the volume of fibrosis in posttransplant hearts. Transplantation 1992; 53: 1047-51.
84. Engels W, Reiters PH, Daemen MJ, et al. Transmural changes in mast cell density in rat heart after infarct induction in vivo. J Pathol 1995; 177: 423-9.
85. Boerma M, Zurcher C, Esveldt I, et al. Histopathology of ventricles, coronary arteries and mast cell accumulation in transverse and longitudinal sections of the rat heart after irradiation. Oncol Reports 2004; 12: 213-9.
86. Kalesnikoff J, Galli SJ. New developments in mast cell biology. Nat Immunol 2008; 9: 1215-23.
87. Galli SJ, Tsai M. Mast cells: versatile regulators of inflammation, tissue remodeling, host defense and homeostasis. J Dermatol Sci 2008; 49: 7-19.
88. Geissler EN, Russell ES. Analysis of the hematopoietic effects of new dominant spotting (W) mutations of the mouse. II. Effects on mast cell development. Exp Hematol 1983; 11: 461-6.
89. Kitamura Y, Go S. Decreased production of mast cells in S1/S1d anemic mice. Blood 1979; 53: 492-7.
90. Kitamura Y, Go S, Hatanaka K. Decrease of mast cells in W/Wv mice and their increase by bone marrow transplantation. Blood 1978; 52: 447-52.
91. Tsujimura T, Hirota S, Nomura S, et al. Characterization of Ws mutant allele of rats: a 12-base deletion in tyrosine kinase domain of c-kit gene. Blood 1991; 78: 1942-6.
92. Horiguchi K, Komuro T. Ultrastructural characterization of interstitial cells of Cajal in the rat small intestine using control and Ws/Ws mutant rats. Cell Tissue Res 1998; 293: 277-84.
93. Morimoto M, Kasugai T, Tei H, et al. Age-dependent amelioration of hypoplastic anemia in Ws/Ws rats with a small deletion at the kinase domain of c-kit. Blood 1993; 82: 3315-20.
94. Niwa Y, Kasugai T, Ohno K, et al. Anemia and mast cell depletion in mutant rats that are homozygous at "white spotting (Ws)" locus. Blood 1991; 78: 1936-41.
95. Boerma M, Fiser WP, Hoyt G, et al. Influence of mast cells on outcome after heterotopic cardiac transplantation in rats. Transpl Int 2007; 20: 256-65.
96. Joseph J, Kennedy RH, Devi S, et al. Protective role of mast cells in homocysteine-induced cardiac remodeling. Am J Physiol Heart Circ Physiol 2005; 288: H2541-5.
97. Boerma M, Wang J, Kulkarni A, et al. Influence of endothelin-1 receptor inhibition on functional, structural and molecular changes in the rat heart after irradiation. Radiat Res 2008; 170: 275-83.
98. Williams RM, Bienenstock J, Stead RH. Mast cells: the neuroimmune connection. Chem Immunol 1995; 61: 208-35.
99. Arizono N, Matsuda S, Hattori T, et al. Anatomical variation in mast cell nerve associations in the rat small intestine, heart, lung, and skin. Similarities of distances between neural processes and mast cells, eosinophils, or plasma cells in the jejunal lamina propria. Lab Invest 1990; 62: 626-34.
100. Laine P, Naukkarinen A, Heikkila L, et al. Adventitial mast cells connect with sensory nerve fibers in atherosclerotic coronary arteries. Circulation 2000; 101: 1665-9.
101. Ito A, Oonuma J. Direct interaction between nerves and mast cells mediated by the SgIGSF/SynCAM adhesion molecule. J Pharmacol Sci 2006; 102: 1-5.
102. Skaper SD, Pollock M, Facci L. Mast cells differentially express and release active high molecular weight neurotrophins. Brain Res Mol Brain Res 2001; 97: 177-85.
103. Schulze W, Fu ML. Localization of alpha 1-adrenoceptors in rat and human hearts by immunocytochemistry. Mol Cell Biochem 1996; 163-164: 159-65.
104. Kay LJ, Peachell PT. Mast cell beta2-adrenoceptors. Chem Immunol Allergy 2005; 87: 145-53.
105. Facoetti A, Fallarini S, Miserere S, et al. Histochemical study of cardiac mast cells degranulation and collagen deposition: interaction with the cathecolaminergic system in the rat. Eur J Histochem 2006; 50: 133-40.
106. Reynier-Rebuffel AM, Mathiau P, Callebert J, et al. Substance P, calcitonin gene-related peptide, and capsaicin release serotonin from cerebrovascular mast cells. Am J Physiol 1994; 267: R1421-9.
107. Shen GH, Grundemar L, Zukowska-Grojec Z, et al. C-terminal neuropeptide Y fragments are mast cell-dependent vasodepressor agents. Eur J Pharmacol 1991; 204: 249-56.
108. Grundemar L, Wahlestedt C, Shen GH, et al. Biphasic blood pressure response to neuropeptide Y in anesthetized rats. Eur J Pharmacol 1990; 179: 83-7.
109. Arzubiaga C, Morrow J, Roberts LJ, et al. Neuropeptide Y, a putative cotransmitter in noradrenergic neurons, induces mast cell degranulation but not prostaglandin D2 release. J Allergy Clin Immunol 1991; 87: 88-93.
110. Moriyama M, Sato T, Inoue H, et al. The neuropeptide neuromedin U promotes inflammation by direct activation of mast cells. J Exp Med 2005; 202: 217-24.
111. Morgan LG, Levick SP, Voloshneyuk TG, et al. A novel technique for isolating functional mast cells from the heart. Inflam Res 2008; 57: 241-6.
112. Hua XY, Back SM, Tam EK. Substance P enhances electrical field stimulation-induced mast cell degranulation in rat trachea. Am J Physiol 1996; 270: L985-91.
113. Janiszewski J, Bienenstock J, Blennerhassett MG. Picomolar doses of substance P trigger electrical responses in mast cells without degranulation. Am J Physiol 1994; 267: C138-45.
114. Saavedra Y, Vergara P. Somatostatin inhibits intestinal mucosal mast cell degranulation in normal conditions and during mast cell hyperplasia. Regul Pept 2003; 111: 67-75.
115. Tuncel N, Tore F, Sahinturk V, et al. Vasoactive intestinal peptide inhibits degranulation and changes granular content of mast cells: a potential therapeutic strategy in controlling septic shock. Peptides 2000; 21: 81-9.
116. Leon A, Buriani A, Dal TR, et al. Mast cells synthesize, store, and release nerve growth factor. Proc Natl Acad Sci USA 1994; 91: 3739-43.
117. Ieda M, Kanazawa H, Ieda Y, et al. Nerve growth factor is critical for cardiac sensory innervation and rescues neuropathy in diabetic hearts. Circulation 2006; 114: 2351-63.
118. Sofroniew MV, Howe CL, Mobley WC. Nerve growth factor signaling, neuroprotection, and neural repair. Annu Rev Neurosci 2001; 24: 1217-81.
119. Corvera CU, Dery O, McConalogue K, et al. Thrombin and mast cell tryptase regulate guinea-pig myenteric neurons through proteinase-activated receptors-1 and-2. J Physiol 1999; 517: 741-56.
120. Saito T, Bunnett NW. Protease-activated receptors: regulation of neuronal function. Neuromol Med 2005; 7: 79-99.
121. Fuder H, Ries P, Schwarz P. Histamine and serotonin released from the rat perfused heart by compound 48/80 or by allergen challenge influence noradrenaline or acetylcholine exocytotic release. Fundam Clin Pharmacol 1994; 8: 477-90.
122. Tam EK, Caughey GH. Degradation of airway neuropeptides by human lung tryptase. Am J Respir Cell Mol Biol 1990; 3: 27-32.
123. Caughey GH, Raymond WW, Wolters PJ. Angiotensin II generation by mast cell alpha-and beta-chymases. Biochim Biophys Acta 2000; 1480: 245-57.
124. Walls AF, Brain SD, Desai A, et al. Human mast cell tryptase attenuates the vasodilator activity of calcitonin gene-related peptide. Biochem Pharmacol 1992; 43: 1243-8.
125. Nesto RW, Phillips RT. Asymptomatic myocardial ischemia in diabetic patients. Am J Med 1986; 80: 40-7.
126. Aring AM, Jones DE, Falko JM. Evaluation and prevention of diabetic neuropathy. Am Fam Physician 2005; 71: 2123-8.
127. Csont T, Csonka C, Kovacs P, et al. Capsaicin-sensitive sensory neurons regulate myocardial nitric oxide and cGMP signaling. Eur J Pharmacol 2003; 476: 107-13.
128. Preibisz JJ. Calcitonin gene-related peptide and regulation of human cardiovascular homeostasis. Am J Hypertens 1993; 6: 434-50.
129. Harada N, Okajima K. Effect of capsaicin on plasma and tissue levels of insulin-like growth factor-I in spontaneously hypertensive rats. Growth Horm IGF Res 2008; 18: 75-81.
130. Peng J, Xiao J, Ye F, et al. Inhibition of cardiac tumor necrosis factor-alpha production by calcitonin gene-related peptide-mediated ischemic preconditioning in isolated rat hearts. Eur J Pharmacol 2000; 407: 303-8.
131. Li YJ, Peng J. The cardioprotection of calcitonin gene-related peptide-mediated preconditioning. Eur J Pharmacol 2002; 442: 173-7.
132. Katona M, Boros K, Santha P, et al. Selective sensory denervation by capsaicin aggravates adriamycin-induced cardiomyopathy in rats. Naunyn Schmiedebergs Arch Pharmacol 2004; 370: 436-43.
133. Limesand KH, Said S, Anderson SM. Suppression of radiationinduced salivary gland dysfunction by IGF-1. PLoS ONE 2009; 4: e4663.
134. Huang XW, Yang J, Dragovic AF, et al. Antisense oligonucleotide inhibition of tumor necrosis factor receptor 1 protects the liver from radiation-induced apoptosis. Clin Cancer Res 2006; 12: 2849-55.
135. Wang J, Qiu X, Kulkarni A, et al. Calcitonin gene-related peptide and substance P regulate the intestinal radiation response. Clin Cancer Res 2006; 12: 4112-8.
136. Yang LL, Arab S, Liu P, et al. The role of endothelin-1 in myocarditis and inflammatory cardiomyopathy: old lessons and new insights. Can J Physiol Pharmacol 2005; 83: 47-62.
137. Kedzierski RM, Yanagisawa M. Endothelin system: the doubleedged sword in health and disease. Annu Rev Pharmacol Toxicol 2001; 41: 851-76.
138. Simard E, Jin D, Takai S, et al. Chymase-dependent conversion of Big endothelin-1 in the mouse in vivo. J Pharmacol Exp Ther 2009; 328: 540-8.
139. Giannessi D, Del RS, Vitale RL. The role of endothelins and their receptors in heart failure. Pharmacol Res 2001; 43: 111-26.
140. Cernacek P, Stewart DJ, Monge JC, et al. The endothelin system and its role in acute myocardial infarction. Can J Physiol Pharmacol 2003; 81: 598-606.
141. Ertl G, Bauersachs J. Endothelin receptor antagonists in heart failure: current status and future directions. Drugs 2004; 64: 1029-40.
142. Sakai S, Miyauchi T, Sakurai T, et al. Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure. Marked increase in endothelin-1 production in the failing heart. Circulation 1996; 93: 1214-22.
143. Piuhola J, Szokodi I, Kinnunen P, et al. Endothelin-1 contributes to the Frank-Starling response in hypertrophic rat hearts. Hypertension 2003; 41: 93-8.
144. Miyauchi T, Masaki T. Pathophysiology of endothelin in the cardiovascular system. Annu Rev Physiol 1999; 61: 391-415.
145. Ehrenreich H, Burd PR, Rottem M, et al. Endothelins belong to the assortment of mast cell-derived and mast cell-bound cytokines. New Biol 1992; 4: 147-56.
146. Maurer M, Wedemeyer J, Metz M, et al. Mast cells promote homeostasis by limiting endothelin-1-induced toxicity. Nature 2004; 432: 512-6.
147. Metsarinne KP, Vehmaan-Kreula P, Kovanen PT, et al. Activated mast cells increase the level of endothelin-1 mRNA in cocultured endothelial cells and degrade the secreted Peptide. Arterioscler Thromb Vasc Biol 2002; 22: 268-73.
148. Schneider LA, Schlenner SM, Feyerabend TB, et al. Molecular mechanism of mast cell mediated innate defense against endothelin and snake venom sarafotoxin. J Exp Med 2007; 204: 2629-39.
149. Yamamura H, Nabe T, Kohno S, et al. Endothelin-1 induces release of histamine and leukotriene C4 from mouse bone marrow-derived mast cells. Eur J Pharmacol 1994; 257: 235-42.
150. Janicki JS, Brower GL, Gardner JD, et al. Cardiac mast cell regulation of matrix metalloproteinase-related ventricular remodeling in chronic pressure or volume overload. Cardiovasc Res 2006; 69: 657-65.
151. Lundequist A, Abrink M, Pejler G. Mast cell-dependent activation of pro matrix metalloprotease 2: A role for serglycin proteoglycandependent mast cell proteases. Biol Chem 2006; 387: 1513-9.
152. Murray DB, Gardner JD, Brower GL, et al. Endothelin-1 mediates cardiac mast cell degranulation, matrix metalloproteinase activation, and myocardial remodeling in rats. Am J Physiol Heart Circ Physiol 2004; 287: H2295-9.
153. Murray DB, Gardner JD, Brower GL, et al. Effects of Non-Selective Endothelin-1 Receptor Antagonism on Cardiac Mast Cell-Mediated Ventricular Remodeling in Rats. Am J Physiol Heart Circ Physiol 2008; 294: H1251-7.
154. Jullien N, Blirando K, Milliat F, et al. Up-regulation of endothelin type a receptor in human and rat radiation proctitis: preclinical therapeutic approach with endothelin receptor blockade. Int J Radiat Oncol Biol Phys 2009; 74: 528-38.
155. Piuhola J, Makinen M, Szokodi I, et al. Dual role of endothelin-1 via ETA and ETB receptors in regulation of cardiac contractile function in mice. Am J Physiol Heart Circ Physiol 2003; 285: H112-8.
156. Clozel M, Gray GA, Breu V, et al. The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo. Biochem Biophys Res Commun 1992; 186: 867-73.